New adjuvants in evolving vaccine strategies

Bibliography

• Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004;82:497-505
   PubMed Web of Science ®Google Scholar
• Ross AL, Brave A, Scarlatti G, Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis 2010;10:305-16
   PubMed Web of Science ®Google Scholar
• Buonaguro FM, Butler-Ransohoff JE. PharmaPlant: the new frontier in vaccines. Expert Rev Vaccines 2010;9:805-7
   PubMed Web of Science ®Google Scholar
• Lindblad EB, Elhay MJ, Silva R, Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 1997;65:623-9
   PubMed Web of Science ®Google Scholar
• Buonaguro FM, Tomesello ML, Buonaguro L. Immune signatures and systems biology of vaccines. In: Marincola FM, Wang E, editors, In immunologic signatures of rejection. Springer Science; New York, USA; 2011. p. 141-67
   Google Scholar
• Buonaguro FM, Tornesello ML, Buonaguro L. Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines 2009;8:1379-98
   PubMed Web of Science ®Google Scholar
• Gasparini R, Amicizia D, Manfredi P, Human papillomavirus vaccination: what is the best choice? A comparison of 16 strategies by means of a decisional model. Epidemiol Infect 2009;137:794-802
   PubMed Web of Science ®Google Scholar
• Alphs HH, Gambhira R, Karanam B, Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 2008;105:5850-5
   PubMed Web of Science ®Google Scholar
• Alunni-Fabbroni M, Littlewood T, Deleu L, Induction of S phase and apoptosis by the human papillomavirus type 16 E7 protein are separable events in immortalized rodent fibroblasts. Oncogene 2000;19:2277-85
   PubMed Web of Science ®Google Scholar
• van der Burg SH. Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding. Expert Rev Vaccines 2008;7:1-5
   PubMed Web of Science ®Google Scholar
• Bousarghin L, Touze A, Gaud G, Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol Cancer Ther 2009;8:357-65
   PubMed Web of Science ®Google Scholar
• Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine 2008;26( Suppl 10):K62-7
   PubMed Web of Science ®Google Scholar
• Garcon N, Chomez P, Van MM. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007;6:723-39
   PubMed Web of Science ®Google Scholar
• Tapping RI, Akashi S, Miyake K, Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol 2000;165:5780-7
   PubMed Web of Science ®Google Scholar
• Baldridge JR, McGowan P, Evans JT, Taking a Toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004;4:1129-38
   PubMed Web of Science ®Google Scholar
• Beran J, Hobzova L, Wertzova V, Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccin 2010;6:578-84
   PubMed Web of Science ®Google Scholar
• Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008;8:235-47
   PubMed Web of Science ®Google Scholar
• Verstraeten T, Descamps D, David MP, Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008;26:6630-8
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Fendrix: EPAR Scientific Discussion. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000550/WC500021700.pdf.2005
   Google Scholar
• Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008;110:S1-10
   PubMed Web of Science ®Google Scholar
• Garcon N, Wettendorff M, Van Mechelen M. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin Biol Ther 2011;11:667-77
   PubMed Web of Science ®Google Scholar
• Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008;181:17-21
   PubMed Web of Science ®Google Scholar
• Tritto E, Mosca F, De GE. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009;27:3331-4
   PubMed Web of Science ®Google Scholar
• Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs 1998;7:1475-82
   PubMedGoogle Scholar
• Kashala O, Amador R, Valero MV, Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine 2002;20:2263-77
   PubMed Web of Science ®Google Scholar
• Velez ID, Gilchrist K, Martinez S, Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 2009;28:329-37
   PubMed Web of Science ®Google Scholar
• Coler RN, Bertholet S, Moutaftsi M, Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011;6:e16333
   PubMed Web of Science ®Google Scholar
• Kester KE, Cummings JF, Ofori-Anyinam O, Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009;200:337-46
   PubMed Web of Science ®Google Scholar
• Wobser M, Keikavoussi P, Kunzmann V, Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006;55:1294-8
   PubMed Web of Science ®Google Scholar
• Saul A, Lawrence G, Allworth A, A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 2005;23:3076-83
   PubMed Web of Science ®Google Scholar
• Aucouturier J, Dupuis L, Deville S, Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002;1:111-18
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 2000;19:1180-7
   PubMed Web of Science ®Google Scholar
• Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine 2009;27:4388-401
   PubMed Web of Science ®Google Scholar
• Moser C, Amacker M, Zurbriggen R. Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines 2011;10:437-46
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Tornesello ML, Tagliamonte M, Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol 2006;80:9134-43
   PubMed Web of Science ®Google Scholar
• Park BS, Song DH, Kim HM, The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009;458:1191-5
   PubMed Web of Science ®Google Scholar
• Jahrsdorfer B, Weiner GJ. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 2008;3:27-32
   PubMedGoogle Scholar
• Vollmer J, Weeratna R, Payette P, Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004;34:251-62
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-5
   PubMed Web of Science ®Google Scholar
• Bargieri DY, Rosa DS, Braga CJ, New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 2008;26:6132-42
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Taylor DN, Tussey L, Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 2010;28:8268-74
   PubMed Web of Science ®Google Scholar
• Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 2010;185:5677-82
   PubMed Web of Science ®Google Scholar
• Vijay-Kumar M, Carvalho FA, Aitken JD, TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin. Eur J Immunol 2010;40:3528-34
   PubMed Web of Science ®Google Scholar
• Nguyen DN, Green JJ, Chan JM, Polymeric materials for gene delivery and DNA vaccination. Adv Mater 2008;20:1-21
   Web of Science ®Google Scholar
• Little SR, Lynn DM, Ge Q, Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc Natl Acad Sci USA 2004;101:9534-9
   PubMed Web of Science ®Google Scholar
• Wloch MK, Smith LR, Boutsaboualoy S, Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 2008;197:1634-42
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Morel S, Lockman L, AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009;183:6186-97
   PubMed Web of Science ®Google Scholar
• Ivory C, Chadee K. DNA vaccines: designing strategies against parasitic infections. Genet Vaccines Ther 2004;2:17
   PubMedGoogle Scholar
• Barouch DH, Santra S, Schmitz JE, Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000;290:486-92
   PubMed Web of Science ®Google Scholar
• Zhang Y, Taylor MG, Johansen MV, Bickle QD. Vaccination of mice with a cocktail DNA vaccine induces a Th1-type immune response and partial protection against Schistosoma japonicum infection. Vaccine 2001;20:724-30
   PubMed Web of Science ®Google Scholar
• Lladser A, Mougiakakos D, Tufvesson H, DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Mol Ther 2011;19:594-601
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Pietersz GA, Tsibanis A, Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res 2006;8:R27
   PubMed Web of Science ®Google Scholar
• Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007;7:790-802
   PubMed Web of Science ®Google Scholar
• Pink JR, Kieny MP. 4th meeting on Novel Adjuvants Currently in/close to Human Clinical Testing World Health Organization – organisation Mondiale de la Sante Fondation Merieux, Annecy, France, 23-25, June 2003. Vaccine 2004;22:2097-102
   PubMedGoogle Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010;33:492-503
   PubMed Web of Science ®Google Scholar